Market News
Smart Trading. Simplified.
Tiny Massachusetts Company Awarded $75 Billion Patent
Tiny biotech's breakthrough proves it's possible to remove cancer cells from sick patients. Bill Gates says new discovery is so powerful it could "help humanity." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $1.57 Million >>>
Sponsored
Why Did Buffett Sell Costco?
Costco Wholesale Corporation (NASDAQ:COST) is a membership warehouse chain that enjoyed huge gains during the panic shopping sprees of 2020. In fact, Berkshire Hathaway vice chairman Charlie Munger serves as a member of the board of directors and personally owns over $60 million of Costco stock. Susan Decker also serves on the board for both […]
My #1 Small Cap Stock for January
Ex-Wall Street CEO Dylan Jovine has racked up big gains in small caps stocks. He's had three picks jump 100%, 111% and 171% just in the past 90 days!
Sponsored
Is BioVie Stock A Buy?
BioVie Inc (NASDAQ: BIVI) speciality is in developing drug therapies for disease of the liver with a special concentration on ascites. BioVie’s FDA candidate BIV201 treats ascites that develop in cases of chronic liver cirrhosis. As healthcare investor focus shifted to vaccines, BioVie has had a mostly down year last year. Still, BIVI share price […]
Small Biotech Firm Stuns World
On November 16, 2016 a small biotech used a radical new treatment to restore blindness in mice. CBS News called this breakthrough "the most consequential discovery in biomedicine this century."
Investors who get in early are set to earn 46,751% returns.
Sponsored
Is Cleanspark Stock A Buy?
Cleanspark Inc. (NASDAQ:CLSK) is a provider of tools for distributed energy resource management systems and microgrids in the form of software controls. The company achieves this aim through control technology solutions that help companies and municipalities manage energy storage and load separation between main power grids and established microgrids. Microgrids are primarily used for their […]
A Rare Opportunity to Turn $1,000 into $481,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Sponsored
How to Invest In Commodities
With Federal Reserve money printing ballooning in the past year, concerns over inflation have risen. Some argue that commodities will rise if inflation kicks off in earnest, and that the mushrooming stock market from the March ’20 lows is evidence of that. Others foretell of commodities rising when confidence in government fractures. Regardless of what […]
New 5G "Arrow" to Replace Nuclear Missiles
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The New York Times reports "No existing defense can stop it." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Sponsored
Qualcomm Vs Marvell Stock: Which Is Best?
Qualcomm, Inc. (NASDAQ:QCOM) and Marvell Technology Group Ltd. (NASDAQ:MRVL) are two semiconductor companies at the heart of the race to 5G. Both make mobile chips, but they have also expanded into a variety of data infrastructure markets to support the Internet of Things (IoT). For investors, which is the better option between Qualcomm vs Marvell […]
My #1 5G Takeover Target forJanuary
Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. On August 6, 2020, he recommended Denali... 60 days later it was up 110% on news of its Biogen deal. On May 8, 2020, he recommended Agio Pharmaceutical options... 3 weeks later it soared 142% on takeover rumors...
Well Dylan just released his #1 5G Takeover Target right here >>>
Sponsored
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment